
Quarterly report 2025-Q3
added 11-13-2025
Milestone Scientific EBITDA 2011-2026 | MLSS
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Milestone Scientific
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -6.72 M | -7.04 M | -8.76 M | -7.3 M | -7.41 M | -3.74 M | -5.58 M | -4.66 M | -6.35 M | -2.96 M | -694 K | 1.18 M | -425 K | -1.12 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 1.18 M | -8.76 M | -4.4 M |
Quarterly EBITDA Milestone Scientific
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -1.11 M | -1.47 M | -1.98 M | - | -1.46 M | -1.77 M | -1.45 M | - | -1.49 M | -2.26 M | -1.33 M | - | -2 M | -2.87 M | -1.9 M | - | -1.96 M | -2.86 M | -963 K | - | -1.46 M | -3.15 M | -1.57 M | - | -921 K | -1.08 M | -792 K | - | -4.2 M | -1.18 M | -1.74 M | - | -1.25 M | -1.52 M | -491 K | - | -1.5 M | -1.97 M | -921 K | - | -815 K | -1.4 M | -65.4 K | - | -150 K | 54.5 K | 333 K | - | 449 K | 1.47 M | 172 K | - | 66.1 K | -43.6 K | -228 K | - | -524 K | -251 K | -116 K |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 1.47 M | -4.2 M | -1.15 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical instruments industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Harvard Bioscience
HBIO
|
-46.8 M | $ 5.16 | -3.37 % | $ 229 M | ||
|
Repro Med Systems
KRMD
|
-2.16 M | $ 4.38 | -1.13 % | $ 202 M | ||
|
LeMaitre Vascular
LMAT
|
78.3 M | $ 109.68 | 1.68 % | $ 2.48 B | ||
|
ICU Medical
ICUI
|
244 M | $ 130.12 | 0.14 % | $ 3.21 B | ||
|
Masimo Corporation
MASI
|
-164 M | $ 178.65 | 0.11 % | $ 9.52 B | ||
|
Luminex Corporation
LMNX
|
72.9 M | - | - | $ 1.75 B | ||
|
Merit Medical Systems
MMSI
|
308 M | $ 68.19 | 0.09 % | $ 4.03 B | ||
|
Akers Biosciences, Inc.
AKER
|
-12.3 M | - | -9.52 % | $ 20.6 M | ||
|
Atrion Corporation
ATRI
|
37.7 K | - | - | $ 810 M | ||
|
Envista Holdings Corporation
NVST
|
332 M | $ 26.24 | 1.61 % | $ 4.41 B | ||
|
OraSure Technologies
OSUR
|
-61.8 M | $ 3.14 | 1.79 % | $ 231 M | ||
|
Pro-Dex
PDEX
|
11.9 M | $ 50.22 | 4.73 % | $ 165 M | ||
|
Ekso Bionics Holdings
EKSO
|
-11.8 M | $ 11.0 | 3.77 % | $ 26.7 M | ||
|
Pulse Biosciences
PLSE
|
-76.5 M | $ 21.22 | 1.39 % | $ 1.43 B | ||
|
Antares Pharma, Inc.
ATRS
|
16.2 M | - | - | $ 955 M | ||
|
Cantel Medical Corp.
CMD
|
123 M | - | -1.18 % | $ 3.4 B | ||
|
CRH Medical Corporation
CRHM
|
33.9 M | - | - | $ 282 M | ||
|
Hill-Rom Holdings, Inc.
HRC
|
518 M | - | -0.05 % | $ 10.3 B | ||
|
Repligen Corporation
RGEN
|
116 M | $ 117.05 | 0.6 % | $ 6.52 M | ||
|
Varian Medical Systems, Inc.
VAR
|
60 M | - | -0.02 % | $ 16.3 B | ||
|
Nephros
NEPH
|
-1.38 M | $ 3.09 | -0.64 % | $ 32.1 M | ||
|
STERIS plc
STE
|
1.34 B | $ 223.39 | 1.08 % | $ 22 B | ||
|
Haemonetics Corporation
HAE
|
337 M | $ 57.41 | -1.8 % | $ 2.89 B | ||
|
Baxter International
BAX
|
673 M | $ 16.68 | 0.45 % | $ 8.56 B | ||
|
Teleflex Incorporated
TFX
|
192 M | $ 107.19 | 1.27 % | $ 4.78 B | ||
|
Isoray
ISR
|
-110 M | - | 0.03 % | $ 108 M | ||
|
AngioDynamics
ANGO
|
-14.2 M | $ 10.57 | -1.34 % | $ 432 M | ||
|
Intuitive Surgical
ISRG
|
3.55 B | $ 473.04 | -1.05 % | $ 169 B | ||
|
AtriCure
ATRC
|
2.64 M | $ 29.58 | -0.67 % | $ 1.41 B | ||
|
InfuSystem Holdings
INFU
|
15 M | $ 9.5 | -1.04 % | $ 196 M | ||
|
Utah Medical Products
UTMD
|
17.4 M | $ 64.81 | -0.49 % | $ 235 M | ||
|
iRhythm Technologies
IRTC
|
-36.7 M | $ 118.7 | 0.47 % | $ 3.8 B | ||
|
BioLife Solutions
BLFS
|
-1.97 M | $ 19.68 | 2.69 % | $ 907 M | ||
|
electroCore
ECOR
|
-12.7 M | $ 6.04 | -1.55 % | $ 51.2 K | ||
|
The Cooper Companies
COO
|
1.06 B | $ 70.5 | 0.36 % | $ 14 B | ||
|
West Pharmaceutical Services
WST
|
756 M | $ 246.63 | 2.17 % | $ 17.8 B | ||
|
Predictive Oncology
POAI
|
-10.8 M | - | - | $ 31.1 M | ||
|
Glaukos Corporation
GKOS
|
-95 M | $ 106.14 | -0.66 % | $ 5.14 B | ||
|
ResMed
RMD
|
1.16 B | $ 230.14 | 0.95 % | $ 33.6 B | ||
|
Microbot Medical
MBOT
|
-9.75 M | $ 2.51 | -0.6 % | $ 25.6 M | ||
|
Retractable Technologies
RVP
|
-13.5 M | $ 0.7 | -3.33 % | $ 21 M | ||
|
DENTSPLY SIRONA
XRAY
|
-70 M | $ 11.71 | 1.43 % | $ 2.33 B | ||
|
NeuroMetrix
NURO
|
-8.69 M | - | 5.05 % | $ 9.02 M | ||
|
STAAR Surgical Company
STAA
|
-83.4 M | $ 19.24 | 3.94 % | $ 954 M | ||
|
Stereotaxis
STXS
|
-21.5 M | $ 1.79 | -2.72 % | $ 163 M | ||
|
Becton, Dickinson and Company
BDX
|
5.04 B | $ 156.65 | 0.27 % | $ 45.1 B | ||
|
Alcon
ALC
|
580 M | $ 74.33 | 0.26 % | $ 40.4 B |